Agenus to Provide Third Quarter 2026 Financial Report and Development Update
Agenus will release its third quarter 2026 financial results before market open on Thursday, November 5, 2026. The release is expected to cover progress on botensilimab and balstilimab (BOT+BAL), including the Phase 3 neoadjuvant ROBBIN trial in earlier-stage colon cancer and the first marketing authorizations for the combination in Armenia.
Key figures
- Earnings date
- 2026-11-05
- Bot bal patients studied
- over 1,500
- Balstilimab patients studied
- more than 900
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.